Ameriprise Financial Inc Athira Pharma, Inc. Transaction History

Ameriprise Financial Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$1.92 - $2.71 $3,840 - $5,420	-2,000 Reduced 10.95%	16,269 $43,000
Q1 2024 May 15, 2024	BUY	$2.24 - $4.15 $40,922 - $75,816	18,269 New	18,269 $50,000
Q2 2023 Aug 14, 2023	BUY	$2.36 - $3.59 $8,647 - $13,153	3,664 Added 31.49%	15,300 $45,000
Q1 2023 May 15, 2023	SELL	$2.26 - $4.22 $51,778 - $96,684	-22,911 Reduced 66.32%	11,636 $29,000
Q4 2022 Feb 14, 2023	BUY	$2.76 - $3.71 $13 - $18	5 Added 0.01%	34,547 $109,000
Q3 2022 Nov 14, 2022	BUY	$2.93 - $3.96 $101,208 - $136,786	34,542 New	34,542 $102,000
Q2 2022 Aug 15, 2022	SELL	$2.74 - $13.43 $1.6 Million - $7.85 Million	-584,550 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$8.96 - $13.51 $1.4 Million - $2.11 Million	156,250 Added 36.48%	584,550 $7.89 Million
Q4 2021 Feb 14, 2022	SELL	$9.17 - $16.39 $126,729 - $226,509	-13,820 Reduced 3.13%	428,300 $5.58 Million
Q3 2021 Nov 15, 2021	BUY	$9.15 - $11.09 $4.05 Million - $4.9 Million	442,120 New	442,120 $4.15 Million

16.9M

112K

68K

Ticker ATHA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,817,700
Market Cap $21.6M
Description
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical tri...

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

Stay updated on Ameriprise Financial Inc with notifications on news.